Yes, 29 patients in the trial got excluded which doesn't help.
The mean figures might well obscure a benefit because of the high proportion who don't respond well to anti VEGF treatment
Overall it would fit the theory that prolonged treatment with anti VEGF-A agents upregulates the other VEGF receptor subtypes which are then blocked by OPT302 for further benefit
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-28
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.8¢ |
Change
-0.028(4.87%) |
Mkt cap ! $667.8M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.0¢ | 53.0¢ | $318.6K | 585.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 87999 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 23784 | 10 |
View Market Depth
| Last trade - 13.18pm 04/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |